A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE

Cancer Screening and Prevention

Cancer Screening and Prevention
Why Choose City of Hope
Sometimes hereditary or genetic factors can increase your risk for cancer.  City of Hope’s Cancer Screening and Prevention Program is designed to help you understand more about your personal cancer risks.  Armed with this knowledge, you can learn how to minimize your risks and stop cancer from developing.  Start here to see how you can do your part to outsmart cancer.
City of Hope's Cancer Screening and Prevention Program offers a comprehensive cancer risk assessment that focuses on family history and genetics, taking into account environmental and lifestyle factors. Following this assessment, the program provides concrete steps you can take to mitigate these risks and help prevent cancer from developing.

Get a comprehensive assessment with a genetic counselor to determine hereditary or genetic risks for the development of cancer. If indicated, patients can choose to use genetic testing to assist with identifying cancer-prevention strategies.
Key indicators of hereditary cancer
Many people believe that cancer strikes randomly, but that’s not always true. Sometimes hereditary or genetic factors increase an individual’s risk for cancer. Recent research clearly indicates a link between genes and cancer.

This link is often strongest in families where:
  • Cancer occurs at a much younger age than average
  • Cancer occurs in several close relatives
  • More than one type of cancer occurs in the same close relative
  • Cancer occurs in paired organs (i.e. cancer in both breasts)
  • Cancer occurs in more than one generation
  • Several rare cancers occur in a family
While some common types of cancer such as breast, ovarian, colorectal or prostate cancer may or may not be inherited, other types of cancer (usually much rarer), are almost always inherited, such as medullary thyroid cancer.
Genetic cancer risk assessment
Although an immediate family history may not suggest an obvious pattern of hereditary cancer, there can still be risk factors discoverable in an extended family history.  Small families may have fewer cases of cancer, or generations may be "skipped" if the cancer expression is sex-limited (meaning a certain kind of cancer only appears in one sex, such as ovarian cancer or prostate cancer).  Ethnic origin of your ancestors also may play a role in determining whether cancer could be hereditary.
Establishing a frame of reference
In order to determine the best course of action in assessing cancer risk, City of Hope develops a basic frame of reference. This involves obtaining an accurate family history regarding the occurrence of cancer(s) in you, your immediate and extended family – your children, siblings, parents, grandparents, aunts, uncles and cousins on both sides. The type of cancer and the age of onset are extremely important in gathering this information.
Initial screening criteria for patients who should have genetic cancer risk
In the assessment, we look at the number of your relatives with cancer, the closeness of their biological relationship to you, and the specific types of cancer in your family.  For more specific information on who should be referred for genetic cancer risk assessment, please see our guidelines.

Genetic Counseling

Genetic testing is a powerful tool, and raises many important issues for individuals and their families. The following are frequently asked questions and important information you should know before deciding if cancer risk testing is useful for you.
What is genetic counseling?
Cancer risk genetic counseling entails consulting with a team of health care professionals (usually a genetic counselor, physician or nurse-geneticist) to review personal and family history, help determine cancer risk, and provide recommendations to reduce cancer risk and detect cancer earlier.
What is the role of the genetic counselor?
A genetic counselor will evaluate the likelihood of a genetic trait that is responsible for cancer in an individual or his/her family and help people understand the genetic, medical, psychological and other issues related to genetic testing.

Genetic counseling before genetic testing helps individuals make a truly informed decision about whether testing is right for them. Similarly, genetic counseling after testing helps to explain the meaning and implications of the test result, including determining if further testing is necessary.
What is genetic testing for cancer risk?
Genetic testing for cancer risk is used to determine if a genetic change, called a mutation, is present in genes that predispose persons to developing cancer at an earlier age than would be expected. Having a predisposition to developing cancer does not mean you will definitely develop cancer, but it does increase your risk. Knowing this may enable you and your doctor to make health care decisions to prevent or reduce your chances for cancer.
What are the benefits of genetic testing?
Testing could identify who is at high risk for particular cancers and who is not. A person found to have a cancer-causing mutation could make health care decisions to prevent or lower his or her chances for cancer or help detect cancer at an early stage. A person who does not have the mutation that is responsible for cancer in their family would not need extra healthcare exams and tests and may be relieved to learn that they, and their children, are not at increased cancer risk because of this mutation. Genetic testing may help determine the cause of cancer for you or your family.
How do genes and heredity affect cancer risk for my children?
Genes are made up of DNA, the hereditary blueprint that makes us who we are. We have two copies of each gene. We get our genes from our parents, inheriting one copy of a gene from our mother and another copy from our father. When a parent has a mutation, there is a 50 percent chance of passing on the mutation to each of his or her children, since each child inherits either the normal copy of the gene or the copy with a mutation.
Are all cancers hereditary?
No. In fact, only about five to 10 percent of all cancers are inherited. Most cancers are due to an accumulation of damage to the DNA in our cells. This occurs naturally as we age, with most cancers occurring at older ages (50+). The development of cancer is a multi-step process. This means that several different changes have to occur in the cell's DNA before cancer develops. An individual who inherits a cancer gene mutation is already one step ahead in this process. Thus, fewer steps have to happen before cancer develops, and cancer may be seen at younger ages than otherwise expected.
What could indicate that I might be at hereditary risk for cancer?
Cancer is a common disease. It is expected that families will have one or more relatives with some form of cancer. Nevertheless, several clues exist to suggest hereditary cancer in a family. These clues include:
  • Cancer at an early age
  • More than one generation with cancers
  • Same type of cancer in at least two closely related relatives
  • Multiple primaries (more than one type of cancer in the same person)
  • Bilateral disease (cancer occurring in both sides of a paired organ, e.g., cancer in both breasts)
  • Multifocal disease (many primary tumors arising in the same organ)
  • Rare cancers clustered in the same side of the family
  • Breast & ovarian cancer in the same side of the family
  • Breast cancer that occurs in a male
  • Colon and uterine cancer in the same side of the family
  • Multiple colo-gastrointestinal polyps in a young individual (e.g., 10 in a person)
The genes involved with cancer can come from either side of the family. Thus, a cancer gene trait may be passed to a daughter through her father who did not have cancer. Accurately interpreting family history information is an essential aspect of genetic counseling.
What if I don't have much information about my family?
Although a large family may provide more clues to interpreting hereditary risk, many of us have small families or limited information available about our family's past. Sometimes various strategies can be used to find out more information, such as contacting relatives, searching for medical records or obtaining copies of death certificates.
What are the limitations of genetic testing?
Because testing techniques vary, it is important that your genetic counseling team explain the method of testing being used to look for a mutation and the chances that method will find a mutation. Different methods have different levels of sensitivity, and therefore, even with the best technology, in some cases testing may not be able to find an existing cancer-causing mutation for you or your family.
Are my test results confidential?
Test results will be part of your medical record and, as all medical records, they will never be shared with anyone other than yourself without your permission, as the law indicates. If your health insurance company paid for your testing, the insurer could ask for the test result. The pros and cons of disclosing your result to others will be discussed with you. Participation in a research study is strictly confidential, as outlined in the requisite informed consent document provided to all study participants.
What are the psychological effects of testing?
Individuals differ in their thoughts about genetic testing for cancer risk, what risk means to them, and ways to manage risk. They might feel that the knowledge gained from testing, regardless of the test result, helps them to feel less uncertain and to make better health care decisions armed with more knowledge. They might feel relieved to know that a genetic change was responsible for cancer rather than something about their lifestyle or environment. Others prefer not to know, or decide that the information learned from testing would not be useful to them, perhaps in that it would not change their health care management or provide information for other family members.

Genetic testing can also affect family relationships. If a family member has a mutation, a relative who learns that she or he does not have the mutation may feel guilty for being spared. People in whom a mutation is identified may feel a change in self-image, fear of the future, anger, surprise, worry or guilt for possibly passing a mutation on to their children. The inability to identify a mutation in a family could also be upsetting to some people. These are all normal reactions.

Some people seek psychological counseling prior to or after testing to help cope with decisions about testing and the implications of test results.
What about possible discrimination due to having a disease-associated mutation?
There has been concern that people identified as at high risk for cancer could be discriminated against when obtaining or retaining health insurance, disability insurance and life insurance, and when obtaining or retaining employment. Further, having a cancer-prone genetic makeup could lead to social stigma and social discrimination in terms of choice of schools or careers, adoption, and even dating and marriage relationships.
What are the legal protections?
In the past, laws at the federal and state levels offered some protection against discrimination based on genetic testing or family history information; however those laws did not offer unqualified full protection. Recently, the Genetic Information Nondiscrimination Act (GINA) was signed into law and provides the most comprehensive protection against genetic discrimination of any law thus far.

Genetic Information Nondiscrimination Act (GINA) of 2008: The Genetic Information Nondiscrimination Act (GINA) is a long-awaited piece of federal legislation prohibiting the use of genetic information in health insurance coverage decisions or employment. This legislation prohibits insurance companies from determining health insurance eligibility or premiums based on genetic test results or family history. In addition, GINA prohibits employers from using genetic information in decisions regarding employment, compensation, conditions or privileges of employment. For more information see Hudson et al. New England Journal of Medicine 358: 2661-63, 2008.

Health Insurance Portability and Accountability Act (HIPAA): In August 1996, HIPAA was signed into law, expressly stating that people who are covered by a group health insurance policy of 50 or more individuals by their employer may not be denied a similar policy due to genetic information or other pre-existing conditions when they change jobs. This law was a first step in providing federal protection against genetic status discrimination. However, it does not protect self-employed individuals or those working for small employers, so the more comprehensive GINA was later passed.

At the state level, California law prohibits prepaid health care plans, self-funded/self-insured employer/employee welfare benefit plans, nonprofit hospital service plans, and life and disability income insurance companies from discrimination based on genetic characteristics to persons unaffected by a genetic-related disorder. Genetic characteristics are defined as a family history of genetic disorders or gene alterations causing or increasing the risk of a disease or disorder.

Ashkenazi Jewish Heritage

Specific BRCA gene mutations found in Ashkenazi Jewish individuals
Two specific mutations in the BRCA1 gene and one mutation in the BRCA2 gene occur predominately in persons of Ashkenazi Jewish descent whose ancestors come from eastern or central Europe. It is estimated that 1 in 40 Ashkenazi men and women carry one of these three mutations. About 90 percent of Jewish persons in the U.S. are of Ashkenazi descent.
Hereditary breast cancer
About five percent of all breast cancers and 10 percent of all ovarian cancers are associated with single-gene inherited changes (mutations), primarily in the BRCA1 and BRCA2 genes. Having a BRCA mutation predisposes women to breast and ovarian cancer. Hundreds of different mutations in these genes have been identified.
Cancer risk
As with any woman who has a cancer-associated BRCA gene mutation, Ashkenazi women with one of these mutations have a significantly increased risk for breast and ovarian cancer. Studies indicate that the average lifetime risk associated with these three specific mutations is about 56 percent for breast cancer and 16 percent for ovarian cancer. This risk may be higher or lower, depending on a woman's personal and family history. Men who have a BRCA mutation also have an increased risk for cancer – about 6 percent for breast cancer and 16 percent for prostate cancer.
Testing for these three mutations
Most Ashkenazi Jewish persons tested for these mutations have a personal or family history of breast or ovarian cancer, or have a blood relative in whom testing has already identified a mutation. Because much is still unknown about cancer genetics, testing is not typically offered to the general population.
Testing is only one of the methods used to estimate cancer risk
Counseling and testing is a multi-step process that begins with assessing cancer risk based on personal factors and family history. This process also includes education and counseling to help understand risk, the usefulness and limitations of genetic testing and other means to assess risk, and individualized options for early detection and risk-reduction strategies. If testing is appropriate and desired, a small blood sample is drawn for analysis. A confidential test result is typically available within two to three weeks. Test results are disclosed in person at a follow-up visit.
Research studies
Ongoing research studies are a vital part of City of Hope's Cancer Screening and Prevention Program's commitment to combating cancer. We will inform you about available studies and eligibility to participate, which is entirely voluntary and will not affect your care in any way.
Hadassah, the Women's Zionist Organization of America, is the largest Jewish membership organization in the United States. Hadassah’s educational programs cover concerns relating to the science of genetics, counseling/psychosocial issues, discrimination and ethics from a Jewish perspective.

The American Jewish Congress - The Congress’ Commission for Women's Equality supports federal and state legislative campaigns to protect genetic privacy and prohibit genetic discrimination in insurance and employment.

Sharsheret provides resources and support for young Jewish women, of all backgrounds, facing breast cancer.


Support This Program

We deliver exquisite care at the leading edge of cancer treatment. It takes the help of a lot of caring people to make hope a reality for our patients. City of Hope was founded by individuals' philanthropic efforts 100 years ago. Their efforts - and those of our supporters today -- have built the foundation for the care we provide and the research we conduct. It enables City of Hope to strive for new breakthroughs and better therapies - helping more people enjoy longer, better lives.

For more information on supporting this specific program, please contact:

Janet Morgan

Senior Director
Phone: 213-241-7250
Email: jmorgan@coh.org

Clinical Cancer Genetics
The City of Hope Division of Clinical Cancer Genetics is committed to being a national leader in the advancement of cancer genetics, screening and prevention, through innovative patient care, research and education.

Contact Us
  • 800-826-HOPE (4673)
  • For more information about the Cancer Screening & Prevention Program, call 626-256-8662, ext. 2.
CCG Newsletter: Closing the Loop
View the current issue: CCG Newsletter
Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
  • Donating blood and platelets saves lives. We all know this. Yet every summer, potential blood donors become distracted by vacations and schedule changes. As a result, blood donations fall dramatically across the nation, leaving hospitals frantically trying to bring in much-needed blood for their patients. Earli...
  • To be a great cancer hospital, you need a great oncology program. Just ask City of Hope – and Becker’s Hospital Review. The health care publishing industry stalwart, described as the “leading hospital magazine for hospital business news and analysis for hospital and health system executives,” recently selected ...
  • Diagnostic errors are far from uncommon. In fact, a recent study found that they affect about 12 million people, or 1 in 20 patients,  in the U.S. each year. With cancer, those errors in diagnosis can have a profound impact. A missed or delayed diagnosis can make the disease that much harder to treat, as the Ag...
  • Eleven years ago, lymphoma patient Christine Pechera began the long road toward a cancer-free life. She had been diagnosed with non-Hodgkin lymphoma and told by doctors elsewhere that her lifespan likely would be measured in months, not years. Refusing to give up, she came to City of Hope for a second opinion. ...
  • Brain surgery is not for the faint of heart. It takes courage, as well as curiosity and compassion. The truly great surgeons also have a desire to find new, and better ways, of healing the brain. Enter Behnam Badie, M.D., chief of neurosurgery at City of Hope. Now a pioneer in brain tumor treatment, Badie enter...
  • Elizabeth Budde, M.D., Ph.D., wants to encourage infighting. She aims to turn the immune system on itself — to the benefit of patients with acute myeloid leukemia, or AML. AML arises when abnormal white blood cells grow out of control, amassing in the bone marrow and interfering with normal blood cell developme...
  • Six, to date; more soon. Outpatient bone marrow transplants, that is. Finding new ways to deliver quality care with the greatest benefit is a priority for a patient-centered institution like City of Hope. For example, not every bone marrow transplant patient needs to check into the hospital for treatment. In fa...
  • The best measure of success in the fight against cancer is in lives saved and families intact, in extra days made special simply because they exist. Yuman Fong, M.D., chair of the Department of Surgery at City of Hope, understands what precedes that special awareness. When cancer strikes, one minute a person ma...
  • In cancer, expertise matters. So do survival rates, patient safety, patient services and many other factors. City of Hope understands this, as does U.S.News & World Report. The magazine’s 2014-2015 list of best hospitals for cancer once again includes City of Hope, ranking the institution 12 out of 900 elig...
  • At 29, Kommah McDowell was a successful young professional engaged to be married to her best friend. She worked in the financial services sector and kick-boxed to keep in shape and to relax. Then came the diagnosis of triple-negative inflammatory breast cancer, a rare and very aggressive form of breast cancer. ...
  • The well-known drug tamoxifen might not always be the best choice for premenopausal women who have undergone treatment for breast cancer and face a heightened risk of recurrence. A new study suggests that the aromatase inhibitor exemestane, or Aromasin, works slightly better than tamoxifen in preventing cancer ...
  • At age 44, Bridget Hanchette, a mother of three from La Crosse, Wisconsin, was diagnosed with grade IV glioblastoma, the most aggressive type of malignant brain tumor. The cancer grows and spreads quickly, making it difficult to treat. Most patients with this diagnosis are not given much hope, but Hanchette’s i...
  • Survival rates for childhood cancer have improved tremendously over the past few decades, but postcancer care hasn’t always kept up. More children than ever are now coping with long-term complications and side effects caused by their disease and treatment — one of those being learning difficulties. A new ...
  • When Sheldon Querido, a retired manufacturer’s representative, was diagnosed with bladder cancer, his doctor told him that he’d need to have his bladder removed – and that he’d have to wear an external urine-collection bag for the rest of his life. “My first response was ‘I donR...
  • To stop smoking, two approaches might be better than one. A new study has found that using the medication varenicline, or Chantix – along with nicotine patches – was more effective than the medicine alone in helping people quit. The study, conducted by Stellanbosch University in Cape Town, South Africa, and pub...